Response to peginterferon alfa-2a (40KD) in HBeAg-negative CHB: on-treatment kinetics of HBsAg serum levels vary by HBV genotype.

No abstract is available for this paper.

• Publication year

  2013

• Venue

  Journal of Hepatology

• Publication date

  2013-12-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1016/j.jhep.2013.07.017PMID 23872601
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• EASL Clinical Practice Guidelines: management of hepatitis C virus infection.

  2014cited by this paper
• Hepatitis B surface antigen levels: association with 5-year response to peginterferon alfa-2a in hepatitis B e-antigen-negative patients

  2012cited by this paper
• Randomised study comparing 48 and 96 weeks peginterferon α-2a therapy in genotype D HBeAg-negative chronic hepatitis B

  2012cited by this paper
• Validation of a stopping rule at week 12 using HBsAg and HBV DNA for HBeAg-negative patients treated with peginterferon alfa-2a.

  2012cited by this paper
• EASL clinical practice guidelines: Management of chronic hepatitis B virus infection.

  2012cited by this paper
• Early serum HBsAg drop: A strong predictor of sustained virological response to pegylated interferon alfa‐2a in HBeAg‐negative patients

  2009cited by this paper
• Influence of genotype on hepatitis B surface antigen kinetics in hepatitis B e antigen-negative patients treated with pegylated interferon-α2a

  2009cited by this paper
• Hepatitis B virus surface antigen levels: A guide to sustained response to peginterferon alfa‐2a in HBeAg‐negative chronic hepatitis B

  2009cited by this paper
• 924 INCREASING RATES OF HBsAg CLEARANCE AND SEROCONVERSION IN PATIENTS WITH HBeAg-NEGATIVE DISEASE TREATED WITH PEGINTERFERON ALFA-2A ± LAMIVUDINE: RESULTS OF 5-YEAR POST-TREATMENT FOLLOW UP

  2009cited by this paper
• Natural history of chronic hepatitis B: special emphasis on disease progression and prognostic factors.

  2008cited by this paper
• Hepatitis B e Antigen-Negative Chronic Hepatitis B: Natural History and Treatment

  2006cited by this paper
• Influence of hepatitis B virus genotypes on the intra‐ and extracellular expression of viral DNA and antigens

  2006cited by this paper
• Peginterferon alfa-2a alone, lamivudine alone, and the two in combination in patients with HBeAg-negative chronic hepatitis B.

  2004cited by this paper
• Outcome of anti-HBe positive chronic hepatitis B in alpha-interferon treated and untreated patients: a long term cohort study.

  2002cited by this paper
• Interferon alpha therapy in HBeAg-negative chronic hepatitis B: new data in support of long-term efficacy.

  2002cited by this paper
• Interferon α Treatment and Retreatment of Hepatitis B e Antigen-Negative Chronic Hepatitis B

  2001cited by this paper
• Interferon alpha treatment and retreatment of hepatitis B e antigen-negative chronic hepatitis B.

  2001cited by this paper
• Long term response to therapy of chronic anti-HBe–positive Hepatitis B is poor independent of type and schedule of interferon

  1999cited by this paper

• HBsAg decline and clearance with peg-IFN therapy added to nucleos(t)ide analogues: an individual participant data meta-analysis of prospective trials (PROSPER)

  2025cites this paper
• Large-scale profile study on hepatitis B surface antigen levels in chronic hepatitis B: implications for drug development targeting functional cure

  2025cites this paper
• Potential role of microRNAs in personalized medicine against hepatitis: a futuristic approach

  2024cites this paper
• An Update on Viral Hepatitis B and C in Mexico: Advances and Pitfalls in Eradication Strategies

  2024cites this paper
• Changes of natural killer cells’ phenotype in patients with chronic hepatitis B in intermittent interferon therapy

  2023cites this paper
• Management and Treatment of Patients with Chronic Hepatitis B: Towards Personalized Medicine

  2022cites this paper
• HBeAg-Negative/Anti-HBe-Positive Chronic Hepatitis B: A 40-Year-Old History

  2022cites this paper
• A simple-to-use tool for predicting response to peginterferon in HBV DNA suppressed chronic hepatitis B patients in China.

  2021cites this paper
• The role of quantitative HBsAg in patients with HBV DNA between 2000–20,000 IU/ml

  2021cites this paper
• Hepatitis B Core-Related Antigen as Surrogate Biomarker of Intrahepatic Hepatitis B Virus Covalently-Closed-Circular DNA in Patients with Chronic Hepatitis B: A Meta-Analysis

  2021cites this paper
• Biological Characterization of Hepatitis B virus Genotypes: Their Role in Viral Replication and Antigen Expression

  2021cites this paper
• Interpretation of HBV Serologies.

  2021cites this paper
• Final analysis of the international observational S-Collate study of peginterferon alfa-2a in patients with chronic hepatitis B

  2020cites this paper
• Rethinking the inactive carrier state: management of patients with low‐replicative HBeAg‐negative chronic hepatitis B and normal liver enzymes

  2020cites this paper
• Editorial: which factors influence HBsAg levels in HBV‐infected patients? Authors' reply

  2020cites this paper
• Efficacy of peg-interferon–nucleoside analog sequential optimization therapy in HBeAg-positive patients with CHB

  2020cites this paper
• Expression Level of Small Envelope Protein in Addition to Sequence Divergence inside Its Major Hydrophilic Region Contributes to More Efficient Surface Antigen Secretion by Hepatitis B Virus Subgenotype D2 than Subgenotype A2

  2020cites this paper
• Usefulness of quantitative hepatitis B surface antigen testing in hepatitis B community-based screening.

  2020cites this paper
• The Different Effects of Nucleotide and Nucleoside Analogues on the Prognosis of HBV-Related HCC After Curative Resection

  2020cites this paper
• Do the circulating Pre‐S/S quasispecies influence hepatitis B virus surface antigen levels in the HBeAg negative phase of HBV infection?

  2020cites this paper
• Antiviral treatment for treatment-naïve chronic hepatitis B: systematic review and network meta-analysis of randomized controlled trials

  2019cites this paper
• The different effects of adefovir dipivoxil and telbivudine on the prognosis of hepatitis b virus-related hepatocellular carcinoma patients after curative resection

  2019cites this paper
• Role of Biomarkers in Guiding Cure of Viral Hepatitis B

  2019cites this paper
• Clinical utility of HBV surface antigen quantification in HBV e antigen-negative chronic HBV infection

  2019cites this paper
• Role of HBsAg Testing in the Management of Patients with Chronic HBV

  2019cites this paper
• A genotype-specific baseline score predicts post-treatment response to peginterferon alfa-2a in hepatitis B e antigen-negative chronic hepatitis B

  2018cites this paper
• Entecavir add-on or switch-to pegylated interferon improves HBsAg clearance in HBe antigen negative chronic hepatitis B patients

  2018cites this paper
• The Role of New Viral Biomarkers in Chronic Hepatitis B: Ready to Use in the Clinical Practice?

  2018cites this paper
• Management of Hepatitis B Virus Infection: 2018 Guidelines from the Canadian Association for the Study of Liver Disease and Association of Medical Microbiology and Infectious Disease Canada.

  2018cites this paper
• Can quantitative hepatitis B surface antigen levels predict the severity of liver disease in genotype E Patients?

  2018cites this paper
• Add‐on peginterferon alfa‐2a to nucleos(t)ide analogue therapy for Caucasian patients with hepatitis B ‘e’ antigen‐negative chronic hepatitis B genotype D

  2018cites this paper
• New viral biomarkers for Hepatitis B: Are we able to change practice?

  2018cites this paper
• Long‐term follow‐up of patients treated with entecavir and peginterferon add‐on therapy for HBeAg‐positive chronic hepatitis B infection: ARES long‐term follow‐up

  2018cites this paper
• Clinical Usefulness of HBsAg Quantification in Patients with Chronic Hepatitis B Infection

  2017cites this paper
• The role of quantitative hepatitis B surface antigen revisited.

  2017cites this paper
• Characterization of contrasting features between hepatitis B virus genotype A and genotype D in small envelope protein expression and surface antigen secretion.

  2017cites this paper
• Clinical Practice Guidelines EASL 2017 Clinical Practice Guidelines on the management of hepatitis B virus infection q European Association for the Study of the Liver

  2017cites this paper
• Kinetics of Hepatitis B Surface Antigen Level in Chronic Hepatitis B Patients who Achieved Hepatitis B Surface Antigen Loss during Pegylated Interferon Alpha-2a Treatment

  2017cites this paper
• Switching to PegIFNα-2b leads to HBsAg loss in patients with low HBsAg levels and HBV DNA suppressed by NAs

  2017cites this paper
• INASL Position Statements on Prevention, Diagnosis and Management of Hepatitis B Virus Infection in India: The Andaman Statements.

  2017cites this paper
• EASL 2017 Clinical Practice Guidelines on the management of hepatitis B virus infection.

  2017cites this paper
• Effect on HBs antigen clearance of addition of pegylated interferon alfa-2a to nucleos(t)ide analogue therapy versus nucleos(t)ide analogue therapy alone in patients with HBe antigen-negative chronic hepatitis B and sustained undetectable plasma hepatitis B virus DNA: a randomised, controlled, open-

  2017cites this paper
• Untypable genotype restriction patterns and surface gene variants of hepatitis B virus isolates.

  2017cites this paper
• Hepatitis B and D

  2017cites this paper
• Long‐term outcome of inactive and active, low viraemic HBeAg‐negative‐hepatitis B virus infection: Benign course towards HBsAg clearance

  2017cites this paper
• What is new on HBsAg and other diagnostic markers in HBV infection?

  2017cites this paper
• Guidelines on the management of hepatitis B virus infection q European Association for the Study of the Liver

  2017cites this paper
• Repeated Measurements of Hepatitis B Surface Antigen Identify Carriers of Inactive HBV During Long-term Follow-up.

  2016cites this paper
• Hepatitis B virus genotypes: epidemiological and clinical relevance in Asia

  2016cites this paper
• Gastroenterología y Hepatología

  2016influential citation
• A fast and low-cost genotyping method for hepatitis B virus based on pattern recognition in point-of-care settings

  2016cites this paper
• Hepatic flares promote rapid decline of serum hepatitis B surface antigen (HBsAg) in patients with HBsAg seroclearance: A long‐term follow‐up study

  2016cites this paper
• Re: Do hepatic flares really promote rapid decline of serum hepatitis B surface antigen (HBsAg) in patients with HBsAg seroclearance?

  2016cites this paper
• A randomized clinical trial of peginterferon alpha‐2b with or without entecavir in patients with HBeAg‐negative chronic hepatitis B: Role of host and viral factors associated with treatment response

  2016cites this paper
• Virus and Host Testing to Manage Chronic Hepatitis B.

  2016cites this paper
• Treatment outcomes and validation of the stopping rule for response to peginterferon in chronic hepatitis B: A Thai nationwide cohort study

  2016cites this paper
• Virological and serological tools to optimize the management of patients with chronic hepatitis B

  2016cites this paper
• CONSORT: Effects of adding adefovirdipivoxil to peginterferon alfa-2a at different time points on HBeAg-positivepatients

  2016cites this paper
• HLA‐C and KIR combined genotype as new response marker for HBeAg‐positive chronic hepatitis B patients treated with interferon‐based combination therapy

  2016cites this paper
• An update on the strategies used for the treatment of chronic hepatitis B in children

  2016cites this paper
• The suppressive effect of nucleos(t)ide analogue treatment on the incidence of hepatocellular carcinoma in chronic hepatitis B patients

  2016cites this paper
• HBsAg and HBeAg in the prediction of a clinical response to peginterferon α-2b therapy in Chinese HBeAg-positive patients

  2016cites this paper
• HBsAg quantification to optimize treatment monitoring in chronic hepatitis B patients

  2015cites this paper
• Sero-Molecular Epidemiology and Risk Factors of Viral Hepatitis in Urban Yemen

  2015cites this paper
• A Review on Therapeutic Management of Chronic Hepatitis B Infection

  2015influential citation
• Hepatitis B virus genotypes and variants.

  2015cites this paper
• Association Between Level of Hepatitis D Virus RNA at Week 24 of Pegylated Interferon Therapy and Outcome.

  2015cites this paper
• Genotypes and viral variants in chronic hepatitis B: A review of epidemiology and clinical relevance.

  2015cites this paper
• Quantification of HBsAg in nucleos(t)ide-naïve patients treated for chronic hepatitis B with entecavir with or without tenofovir in the BE-LOW study.

  2015cites this paper
• Adeno-Associated Virus Vector Mediated Delivery of the HBV Genome Induces Chronic Hepatitis B Virus Infection and Liver Fibrosis in Mice

  2015cites this paper
• Pegylated-Interferon Alpha Therapy for Treatment-Experienced Chronic Hepatitis B Patients

  2015cites this paper
• Total Hepatitis B Core Antigen Antibody, a Quantitative Non-Invasive Marker of Hepatitis B Virus Induced Liver Disease

  2015cites this paper
• New paradigms in hepatitis B management: only diamonds are forever.

  2015cites this paper
• Rapid fluorescent lateral-flow immunoassay for hepatitis B virus genotyping.

  2015cites this paper
• Response-guided therapy of regimens based on PEG-interferon for chronic hepatitis B using on-treatment hepatitis B surface antigen quantification: a meta-analysis

  2015cites this paper
• Can We Predict Sustained Virologic Response to Interferon α Therapy in Patients With Chronic Hepatitis Delta Virus Infection?

  2015cites this paper
• Therapies for Chronic Hepatitis B: Review of Indications, Outcomes and New Tools for Tailoring Treatments to Patients

  2014cites this paper
• Molecular Epidemiology and Genotyping of Hepatitis B Virus of HBsAg-Positive Patients in Oman

  2014cites this paper
• HBsAg quantification: useful for monitoring natural history and treatment outcome

  2014cites this paper
• A Serum MicroRNA Signature Is Associated with the Immune Control of Chronic Hepatitis B Virus Infection

  2014cites this paper
• Interferon Therapy of Chronic Hepatitis B

  2014cites this paper
• Response-guided Peginterferon Therapy for HBeAg-positive and HBeAg-negative Chronic Hepatitis B using Hepatitis B Surface Antigen Levels: A Review

  2014cites this paper
• HBeAg‐negative chronic hepatitis B: why do I treat my patients with pegylated interferon‐alfa?

  2014cites this paper
• A randomized, open-label clinical study of combined pegylated interferon Alfa-2a (40KD) and entecavir treatment for hepatitis B "e" antigen-positive chronic hepatitis B.

  2014cites this paper
• Chronic hepatitis B: Advances in treatment.

  2014cites this paper
• Hepatitis B surface antigen quantification in chronic hepatitis B and its clinical utility

  2014cites this paper
• Update on Hepatitis B Virus Infection: Focus on Treatment

  2014cites this paper
• Comparison of each HBs antigen assay and it^|^apos;s clinical utility

  2014cites this paper
• [Is quantification of HBsAg levels useful in the follow-up of patients with chronic hepatitis B virus infection?].

  2014cites this paper
• Commentary: HBsAg levels as predictor of sustained response to peginterferon in HBeAg‐negative chronic hepatitis B – author's reply

  2012cites this paper
• Clinical Implications of HBsAg Quantification in Patients with Chronic Hepatitis B

  2012cites this paper